NEWS: FDA experts spurn Abbott drug
- View SourceAdvisory panel recommends full agency not approve atrasentan, a
treatment for prostate cancer.
September 13, 2005: 2:46 PM EDT
By Aaron Smith, CNN/Money staff writer
NEW YORK (CNN/Money) - An FDA expert panel voted unanimously Tuesday
not to recommend atrasentan, an Abbott Laboratories drug candidate that
the company says would stop the spread of prostate cancer and fight